News
SNY, BMY, REGN and others ramp up 2025 dealmaking as pharma/biotech giants chase innovation across key growth areas.
Zacks Investment Research on MSN6d
REGN Strengthens Obesity Pipeline: Will the Move Revive the Stock?Regeneron Pharmaceuticals, Inc. REGN is looking to make inroads in the lucrative obesity market. The company recently entered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback